China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial of its SCB-2019 (CpG 1018/Alum) COVID-19 vaccine in adolescents aged 12 to 17. The study demonstrated superior immune response in teenagers compared to young adults, reinforcing the vaccine’s efficacy.
Study Highlights
- Primary Endpoint Achieved: The trial enrolled 1,278 teenagers, showing a 2-fold higher neutralizing immune response than in adults aged 18–25.
- Safety and Efficacy: SCB-2019 was well-tolerated, with no serious adverse events reported.
- Adult Trial Data: In prior studies, the vaccine provided 100% protection against severe COVID-19 and 95% protection against hospitalization at five months post-vaccination.
Global Regulatory Strategy
Clover Bio plans to submit adolescent-use data to regulators worldwide, including the NMPA, EMA, and WHO, alongside existing filings for adults and the elderly.-Fineline Info & Tech
